RSV Vaccine Shows Hopeful Early Results In 50 To 59-Year-Olds, GSK Says

RSV Vaccine Shows Hopeful Early Results In 50 To 59-Year-Olds, GSK Says

Upworthy

Published

Drugmaker GSK on Wednesday announced promising preliminary results from a late-state trial of its RSV vaccine in people aged 50 to 59, offering hope of expanding access to the landmark shot and boosting efforts to combat the common and potentially deadly respiratory infection. GSK said the…

#drugmaker #rsv #gsk #arexvy #tonywood #cdc #pfizer #abrysvo #sanofi #fda

Full Article